Hugo is about to joust da Vinci. It’s not a battle between Renaissance geniuses. Instead, a commercial fight is brewing ...

In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its ...

With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

Medtronic’s Hugo robotic surgery system earns FDA clearance, ending Intuitive’s long-held dominance and reshaping the future of soft-tissue robotics.

Medtronic (NYSE: MDT) announced today that the FDA cleared its Hugo robotic-assisted surgery system for use in urologic surgical procedures.

The long-awaited FDA clearance sets up a showdown in the surgical robotics market between Medtronic and Intuitive Surgical.

Hugo is heading to the U.S., with Medtronic finally securing a stateside clearance for its robotic surgery platform. | The ...

Medtronic's Hugo surgical robot gained FDA clearance for urologic procedures, opening U.S. market entry and setting the stage ...

If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.

FDA clears Medtronic robot for urologic surgeries, enabling use in prostatectomy, nephrectomy and cystectomy across select U.S. hospitals.

Minneapolis-based Medtronic, the world’s largest standalone medical device manufacturer, is developing a new robotic surgical system expected to be released by 2019. Robotically assisted surgery ...